Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.
Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, Kim I, Stevens DA, Fiedler W, Pagoni M, Samoilova O, Hu Y, Anagnostopoulos A, Bergeron J, Hou JZ, Murthy V, Yamauchi T, McDonald A, Chyla B, Gopalakrishnan S, Jiang Q, Mendes W, Hayslip J, Panayiotidis P. Wei AH, et al. Among authors: fiedler w. Blood. 2020 Jun 11;135(24):2137-2145. doi: 10.1182/blood.2020004856. Blood. 2020. PMID: 32219442 Free PMC article. Clinical Trial.
A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE. Fiedler W, et al. Blood. 2003 Oct 15;102(8):2763-7. doi: 10.1182/blood-2002-10-2998. Epub 2003 Jul 3. Blood. 2003. PMID: 12843001 Free article. Clinical Trial.
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Fiedler W, Serve H, Döhner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK. Fiedler W, et al. Blood. 2005 Feb 1;105(3):986-93. doi: 10.1182/blood-2004-05-1846. Epub 2004 Sep 30. Blood. 2005. PMID: 15459012 Free article. Clinical Trial.
Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.
Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A. Thol F, et al. Among authors: fiedler w. Blood. 2010 Jul 29;116(4):614-6. doi: 10.1182/blood-2010-03-272146. Epub 2010 Apr 26. Blood. 2010. PMID: 20421455 Free article.
Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J, Ganser A. Damm F, et al. Among authors: fiedler w. Blood. 2011 Apr 28;117(17):4561-8. doi: 10.1182/blood-2010-08-303479. Epub 2011 Mar 3. Blood. 2011. PMID: 21372155 Free article.
CD146: a new partner for VEGFR2.
Wellbrock J, Fiedler W. Wellbrock J, et al. Among authors: fiedler w. Blood. 2012 Sep 13;120(11):2164-5. doi: 10.1182/blood-2012-07-439646. Blood. 2012. PMID: 22977083 Free article. No abstract available.
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma.
Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger JS, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas-Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens JB, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S. Ben-Batalla I, et al. Among authors: fiedler w. Blood. 2013 Oct 3;122(14):2443-52. doi: 10.1182/blood-2013-03-491431. Epub 2013 Aug 27. Blood. 2013. PMID: 23982172 Free article.
Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy.
Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Döhner H, et al. Among authors: fiedler w. Blood. 2014 Aug 28;124(9):1426-33. doi: 10.1182/blood-2014-03-560557. Epub 2014 Jul 8. Blood. 2014. PMID: 25006120 Free PMC article. Clinical Trial.
382 results